By Benjamin Chiou
Date: Tuesday 21 May 2024
(Sharecast News) - AstraZeneca has unveiled medium-term growth targets to nearly double group revenues by the end of the decade as it predicts significant growth from existing oncology, biopharmaceuticals and rare disease portfolios.
The pharma giant said it expects to total revenues to hit $80bn by 2030, helped by the...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news